Composition useful for the prevention or reduction of the progression of prostate cancer

1. A composition for inhibiting or reducing the progression of prostate cancer in a patient consisting essentially of, as active ingredients, green tea extract in an amount of from 25 to 800 mg, pomegranate extract in an amount of from 25 to 800 mg, lycopene in an amount of from 0.03 to 30.0 mg, selenium in an amount of from 8.2 to 500 μg, zinc in an amount of from 1 to 200 mg, Serenoa repens extract in an amount of from 10 to 400 mg, soya isoflavonoids in an amount of from 10 to 500 mg, and L-carnitine in an amount of from 50 to 500 mg.

2. The composition of claim 1 , wherein the green tea extract is present in an amount of 250 mg; the pomegranate extract is present in an amount of 250 mg; the lycopene is present in an amount of 1.25 mg; the selenium is present in an amount of 82.5 μg; and the zinc is present in an amount of 20 mg.

3. The composition of claim 1 , wherein the green tea extract is present in an amount of 125 mg; the pomegranate extract is present in an amount of 125 mg; the lycopene is present in an amount of 5 mg; the selenium is present in an amount of 82.5 μg; the zinc is present in an amount of 20 mg; the Serenoa repens extract is present in an amount of 160 mg; and the soya isoflavonoids are present in an amount of 100 mg.

4. The composition of claim 1 , wherein the green tea extract is present in an amount of 125 mg; the pomegranate extract is present in an amount of 40 mg; the lycopene is present in an amount of 5 mg; the selenium is present in an amount of 55 μg; the zinc is present in an amount of 20 mg; the Serenoa repens extract is present in an amount of 320 mg; and the soya isoflavonoids are present in an amount of 100 mg.

5. The composition of claim 1 , wherein the green tea extract is present in an amount of 125 mg; the pomegranate extract is present in an amount of 125 mg; the lycopene is present in an amount of 5 mg; the selenium is present in an amount of 82.5 μg; the zinc is present in an amount of 20 mg; the Serenoa repens extract is present in an amount of 160 mg; the soya isoflavonoids are present in an amount of 100 mg; and the L-carnitine is present in an amount of 200 mg.

6. A method for inhibiting or reducing the progression of prostate cancer, comprising administering an effective amount of the composition of claim 1 to a patient in need thereof.

7. The method according to claim 6 , further comprising administering co-enzymes, mineral substances, antioxidants, vitamins and agents useful for treating prostate cancer to the patient.